Can New Research Improve Artificial Vision for Retinitis Pigmentosa?
Skitterphoto / Pixabay

Can New Research Improve Artificial Vision for Retinitis Pigmentosa?

For patients who lose their vision, artificial and implantable devices like retinal prostheses offer a way forward. But while these prostheses are already somewhat effective, a Korean research team recently…

Continue Reading Can New Research Improve Artificial Vision for Retinitis Pigmentosa?
X-Linked Retinitis Pigmentosa Investigative Gene Therapy is Looking Promising
source: pixabay.com

X-Linked Retinitis Pigmentosa Investigative Gene Therapy is Looking Promising

Janssen Pharmaceuticals has an ongoing Phase 1/2 clinical trial for the inherited retinal disease X-linked retinitis pigmentosa (XLRP). They are investigating an adeno-associated gene therapy called RPGR as a therapeutic…

Continue Reading X-Linked Retinitis Pigmentosa Investigative Gene Therapy is Looking Promising
Gene Therapy Could Cure Irreversible Blindness for X-Linked Retinitis Pigmentosa
source: pixabay.com

Gene Therapy Could Cure Irreversible Blindness for X-Linked Retinitis Pigmentosa

As reported in Biospace, a new gene therapy has made notable progress towards curing x-linked retinitis pigmentosa, a disease responsible for sight loss in men. Until now, the disease irreversibly…

Continue Reading Gene Therapy Could Cure Irreversible Blindness for X-Linked Retinitis Pigmentosa

The World’s First Editing of DNA in Humans Using CRISPR to Treat Leber Congenital Amaurosis

  Allergan plc, a leading global pharmaceutical company, and its partner, Editas Medicine, Inc. have been given the green light for a clinical trial designed to treat patients with severe…

Continue Reading The World’s First Editing of DNA in Humans Using CRISPR to Treat Leber Congenital Amaurosis

Company Cleared to Begin Trials for Experimental Retinitis Pigmentosa Drug

According to a story from globenewswire.com, the drug developer ProQR Therapeutics N.V. has recently announced that the US Food and Drug Administration (FDA) has officially cleared the company's Investigational New…

Continue Reading Company Cleared to Begin Trials for Experimental Retinitis Pigmentosa Drug

Learn About These Rare Eye Diseases to Honor Healthy Vision Month!

May is Healthy Vision Month! Rare disease or not, maintaining healthy eye health should be a priority for all of us. The National Institute of Health has resources for not…

Continue Reading Learn About These Rare Eye Diseases to Honor Healthy Vision Month!

Enrollment Completed in Achromatopsia and Retinitis Pigmentosa Clinical Trials

ACHM and XLRP Achromatopsia (ACHM) is a rare, inherited retinal disease which causes impaired cone photoreceptor function. Patients experience light sensitivity so extreme that it can cause blindness during the…

Continue Reading Enrollment Completed in Achromatopsia and Retinitis Pigmentosa Clinical Trials

New Potential Gene Therapy for Retinal Degeneration Granted ODD

Ocugen Pharmaceuticals has just received their first ever orphan drug designation by the FDA for a gene therapy treatment. It's called OCU400 and it's being investigated as a treatment for…

Continue Reading New Potential Gene Therapy for Retinal Degeneration Granted ODD
Single Use Gene Therapy Approved in the EU for Leber’s Congenital Amaurosis
Free-Photos / Pixabay

Single Use Gene Therapy Approved in the EU for Leber’s Congenital Amaurosis

According to a story from pm360online.com, the drug developer Novartis has recently announced that the company's gene therapy Luxturna has gained approval in the EU as a treatment for Leber's…

Continue Reading Single Use Gene Therapy Approved in the EU for Leber’s Congenital Amaurosis

First Patient Receives Treatment in Retinitis Pigmentosa Clinical Trial

According to a story from BioPortfolio, the biopharmaceutical company GenSight Biologics recently announced that the first patient has received treatment in a Phase I/II clinical trial testing the company's experimental…

Continue Reading First Patient Receives Treatment in Retinitis Pigmentosa Clinical Trial
Preliminary Data from a Phase 1/2 Study of a Gene Therapy for X-Linked Retinitis Pigmentosa has been Shared
Free-Photos / Pixabay

Preliminary Data from a Phase 1/2 Study of a Gene Therapy for X-Linked Retinitis Pigmentosa has been Shared

Nightstar Therapeutics has released preliminary data from a Phase 1/2 study of an experimental gene therapy designed to treat X-linked retinitis pigmentosa. For more detailed information you can view the…

Continue Reading Preliminary Data from a Phase 1/2 Study of a Gene Therapy for X-Linked Retinitis Pigmentosa has been Shared
This Company is Working on Treatment for Rare Retinal Diseases
StockSnap / Pixabay

This Company is Working on Treatment for Rare Retinal Diseases

According to a story from Eye on the Cure, the biopharmaceutical company Ophthotech is hard at work researching and developing gene therapy solutions for a variety of rare retinal conditions.…

Continue Reading This Company is Working on Treatment for Rare Retinal Diseases
Mother Of Sons With Retinitis Pigmentosa Becomes Powerful Advocate For Rare Diseases
Free-Photos / Pixabay

Mother Of Sons With Retinitis Pigmentosa Becomes Powerful Advocate For Rare Diseases

When Kristen Smedley learned her son, Michael, was diagnosed with retinitis pigmentosa, she decided she wouldn't sit back and watch it take away from her son's life, she would take…

Continue Reading Mother Of Sons With Retinitis Pigmentosa Becomes Powerful Advocate For Rare Diseases
Close Menu